Xilio Therapeutics (XLO) Gains from Investment Securities (2025 - 2026)
Xilio Therapeutics (XLO) reported Gains from Investment Securities of -$3.3 million for Q1 2026, up 84.49% sequentially from -$21.3 million in Q4 2025.
Xilio Therapeutics (XLO) Gains from Investment Securities (2025 - 2026) Analysis & Trends
Xilio Therapeutics (XLO) has 2 years of Gains from Investment Securities data on file, last reported at -$3.3 million in Q1 2026.
- For the quarter ending Q1 2026, Gains from Investment Securities changed N/A year-over-year to -$3.3 million; the trailing twelve-month figure through Mar 2026 stood at -$9.1 million (changed N/A YoY), and the FY2025 full-year result was -$5.8 million, changed N/A from the prior year.
- Gains from Investment Securities advanced to -$3.3 million in Q1 2026, from -$21.3 million in the prior quarter.
- In the past five years, Gains from Investment Securities ranged from a high of $15.4 million in Q3 2025 to a low of -$21.3 million in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - |
| 10 | Xilio Therapeutics | 148.60 Mn | -1.70 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -3.30 Mn |
| Mar 31, 2026 | -3.30 Mn |
| Dec 31, 2025 | -21.28 Mn |
| Dec 31, 2025 | -21.28 Mn |
| Sep 30, 2025 | 15.38 Mn |
| Sep 30, 2025 | 15.38 Mn |
| Jun 30, 2025 | 50,000.00 |
| Jun 30, 2025 | 50,000.00 |